 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...6465666768697071727374...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Overcoming acquired cetuximab resistance in head and neck squamous cell carcinoma: An in vitro study on the potential of PI3K inhibition () - Mar 11, 2021 - Abstract #AACR2021AACR_3698;
Preliminary results also show an additive to synergistic interaction between both drugs in the SCC22b-PBS and SCC22b-R cell lines.In conclusion, these results can serve as a preclinical rationale for a novel therapeutic strategy combining buparlisib with cetuximab in HNSCC patients who experience acquired cetuximab resistance. Further research is necessary to obtain a more profound understanding of the molecular mechanisms underlying this targeted combination therapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Targeting MET and RON to overcome cetuximab resistance in colorectal cancer () - Mar 11, 2021 - Abstract #AACR2021AACR_3688;
A comparative RNA-seq analysis showed that PDXs with high pMET/pRON levels could be segregated from PDXs with low pMET/pRON levels. Differential response of these PDXs and their organoid (PDO) derivatives for cetuximab resistance and response to crizotinib addition based on their pMET/pRON levels will be presented.
- APX701 / Apexigen, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
[VIRTUAL] Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor () - Mar 11, 2021 - Abstract #AACR2021AACR_3347;
Together, these data demonstrate the unique binding profile of APX701 and its ability to potently reactivate myeloid cell-mediated anti-tumor immunity. Our data support the development of APX701, a promising myeloid checkpoint inhibitor, for the treatment of cancer.
- CLEC-1 mAbs / OSE Immunotherapeutics, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
[VIRTUAL] CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation () - Mar 11, 2021 - Abstract #AACR2021AACR_2776;
We generated hCLEC-1 knock-in mice and in vivo preclinical evaluation of CLEC-1 blocking mAbs is ongoing. Altogether, these data illustrate that CLEC-1 broadly notably inhibits tumor-cell phagocytosis and synergized with tumor-targeted cytotoxic monoclonal antibodies in both solid and hematological tumors, and hampers DC antigen cross-presentation.
- Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A phase I study of avelumab, palbociclib, and cetuximab (APC) in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) () - Mar 11, 2021 - Abstract #AACR2021AACR_2577;
P1
The RP2D is A 10 mg/kg every 2 wks, C 400 mg/m2 x 1 then 250 mg/m2 wkly, and P 125 mg daily, 3 wks on, one wk off. Promising response rates were seen, and several pts have had durable responses.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] 3D spheroid: A rapid drug screening model for epigenetic clinical targets against heterogenic cancer stem cells. () - Mar 11, 2021 - Abstract #AACR2021AACR_1891;
The Cancer Stem Cells Therapeutic Target Database Version 2.0 (CSCTTv2.0) reported the highest expression of CSCs in glioblastomas, oral and CRCs that showed resistance to anticancer drugs (such as Bevacizumab, 5-FU, cisplatin, cetuximab, oxaliplatin)...We also found from Cytoscape analysis of Reactome network that UniProtKB - P61073 (CXCR4_HUMAN) has significant interaction with other target network genes from 106 network data and it has been mentioned that Plerixafor, an antagonist inhibits CXCR4 activity. Therefore, it is important in designing any small molecules or drugs against heterogenic CSCs of glioblastomas, oral, and CRC with epigenetic target of histone bivalent modifications using a 3D spheroid model which could be rapid screening model for anticancer drug discovery and our current study highlighted this important relationship.
- FT536 / Fate Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
[VIRTUAL] FT536: Preclinical development of a novel off-the-shelf CAR-MICA/B NK cell immunotherapy combined with radiation and antibody treatments as a first-of-kind pan-cancer targeting strategy () - Mar 11, 2021 - Abstract #AACR2021AACR_1414;
Ongoing work is focused on the development of in vivo models that combine FT536 with in situ tumor irradiation and mAbs in order to promote durable responses and the elimination of resistant and heterogenous cancer cells. These data demonstrate successful targeting of MICA/B positive tumors by FT536 can be augmented by mAb and radiation therapies as first-of-kind combinatorial strategies to broadly target escape-prone tumors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Alterations of DNA damage response(DDR) signaling in the development of antibody-dependent cellular cytotoxicity (ADCC) resistance () - Mar 11, 2021 - Abstract #AACR2021AACR_1401;
Here we describe a NK cell-mediated and cetuximab-dependent in vitro model of antibody-dependent cellular cytotoxicity (ADCC) to study alterations of DNA damage response signaling in the process of resistance development...Modulation of DDR signaling by ataxia telangiectasia mutated (ATM) or ATM-Rad3-related (ATR) inhibitors, p53 or STAT1 inhibition by siRNAs or the Janus Kinase 1(JAK1)/STAT1 inhibitor, ruxolitinib, potentiated ADCC activity in ADCC-sensitive A431 cells but not in their ADCC-resistant variants...Blocking DDR components might delay or prevent the evolution of the immunotherapy resistance. Further elucidation of critical signaling pathways involved in ADCC sensitivity and resistance will improve the ability to overcome antibody-based immunotherapy resistance.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Role of NK and CD8+T cells in the antitumor effect elicited by combined treatment with radiation, tumor-specific antibody, and IL2 in a syngeneic murine model of head and neck squamous cell carcinoma () - Mar 11, 2021 - Abstract #AACR2021AACR_1394;
In a syngeneic murine model of HNSCC, the local combination of RT, cetuximab, and IL2 destroys the targeted tumor and enables this site to serve as a potent immune stimulus and personalized source of antigenicity for activation of adaptive T cell immunity. NK cells are necessary for the activation of this ISV effect and the resulting CD8+ T cell-dependent systemic antitumor response.
- LY3537982 / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor () - Mar 11, 2021 - Abstract #AACR2021AACR_463;
Together these data suggest that in certain biologic contexts, broader and more durable anti-tumor activity could be achieved with combination regimens. A first-in-human Phase 1 clinical trial is planned for 2021.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Co-expression and predictive value of HER family members for the response to therapy with cetuximab in patients with metastatic colorectal cancer () - Mar 11, 2021 - Abstract #AACR2021AACR_297;
Of these, cetuximab and panitumumab have been approved for the treatment of patients with metastatic colorectal cancer (mCRC). Our results implicate the importance of large prospective investigation of the expression level and predictive value of not only the therapeutic target (i.e. EGFR protein) but also its dimerization partners for the response to therapy with anti-EGFR mAbs and other forms of HER inhibitors in both the primary tumours and metastatic sites in colorectal cancer.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Expression of exosomal let-7g in biofluids and outcome in colon cancer patient treated with anti-EGFR therapy () - Mar 11, 2021 - Abstract #AACR2021AACR_19;
Our data suggest that let-7g microRNA might function as a paracrine mediator of anti-EGFR resistance and might be exploited as a non-invasive biomarker of resistance to cetuximab treatment. Further work is ongoing to characterize the molecular mechanisms underpinning let-7g mediated effect on anti-EGFR sensitivity in RAS wt CRC cells.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines. (Pubmed Central) - Mar 11, 2021
Consequently, we suggest that the evaluation of NEU3 expression cannot entirely substitute the evaluation of EGFR because EGFR-negative cases cannot be stimulated by NEU3. Furthermore, NEU3-mediated hyperactivation of EGFR is counterbalanced by the administration of cetuximab, hypothesizing that a combined treatment of NEU3- and EGFR-targeted therapies may represent a valid option for CRC patients, which must be investigated in the future.
- || Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 11, 2021
P2, N=83, Recruiting, Sponsor: Assuntina G. Sacco, MD
Furthermore, NEU3-mediated hyperactivation of EGFR is counterbalanced by the administration of cetuximab, hypothesizing that a combined treatment of NEU3- and EGFR-targeted therapies may represent a valid option for CRC patients, which must be investigated in the future. Trial completion date: May 2020 --> May 2022 | Trial primary completion date: Dec 2019 --> Dec 2021
- |||||||||| Krazati (adagrasib) / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Combination therapy, Metastases: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (clinicaltrials.gov) - Mar 10, 2021
P3, N=420, Not yet recruiting, Sponsor: Mirati Therapeutics Inc.
- ||| garsorasib (D-1553) / InventisBio
Enrollment open, Metastases: KEYNOTE-C15: Study to Evaluate D-1553 in Subjects With Solid Tumors (clinicaltrials.gov) - Mar 9, 2021
P1/2, N=200, Recruiting, Sponsor: InventisBio Inc.
Trial completion date: May 2020 --> May 2022 | Trial primary completion date: Dec 2019 --> Dec 2021 Not yet recruiting --> Recruiting
- monalizumab (IPH2201) / AstraZeneca, Innate, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
[VIRTUAL] Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial () - Mar 9, 2021 - Abstract #ESMOBC2021ESMO_BC_250;
P2
Before and on-treatment blood and biopsies will be used for translational research to explore treatment-induced intra-tumoral and systemic changes with a focus on NK-cells and CD8+ T-cells. The MIMOSA-trial is currently open for enrollment at the Netherlands Cancer Institute.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
New P1/2 trial, Combination therapy, Metastases: VIC-BRAFMT-mCRC: Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 9, 2021
P1/2, N=37, Recruiting, Sponsor: Sun Yat-sen University
- || simlukafusp alfa (RG7461) / Roche, Herceptin (trastuzumab) / Roche
Enrollment closed, Combination therapy: A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (clinicaltrials.gov) - Mar 9, 2021
P1a/1b, N=134, Active, not recruiting, Sponsor: Hoffmann-La Roche
The MIMOSA-trial is currently open for enrollment at the Netherlands Cancer Institute. Recruiting --> Active, not recruiting
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Clinical, Reimbursement: My morning-“The insurance company has denied your request for lonsurf because you haven’t tried cetuximab or panitumumab for right sided kras mutant metastatic CRC in 30-something year old patient” clearly documented in the note. yup #MedTwitter #oncology2021 (Twitter) - Mar 9, 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Preclinical, Journal: Radioresistance of KRAS/TP53-Mutated Lung Cancer can be overcome by Radiation Dose Escalation or EGFR Tyrosine Kinase Inhibition In Vivo. (Pubmed Central) - Mar 9, 2021
Despite the known unresponsiveness of KRASmut tumours to EGFR inhibitors, erlotinib radiosensitized KRASmut tumours. Our data highlight KRAS/TP53 co-mutation as a candidate biomarker of radioresistance that can be at least partially reversed by dose escalation or the addition of a targeted agent.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines. (Pubmed Central) - Mar 9, 2021
The present study was performed to design an immunotoxin consisting of engineered RNase A and scFv of Cetuximab...The result of cytotoxicity showed that the engineered immunotoxin could induce cell death to Her1-positive cell lines with an IC of 50 nM. It appears that scFv-engineered RNase A can be a promising molecule for use.
- | Journal: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. (Pubmed Central) - Mar 9, 2021
Finally, with ELISA and flow cytometry, we observed that a single cleavage of IgG1 TmAbs greatly decreased their affinity for FcγRIIIA and C1q and their ability to induce FcγRIIIA-dependent functional responses of NK cells. Overall, our results indicate that the cleavage of the hinge region should be considered with TmAbs treatment and in the development of new molecules.
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: #TumorBoardTuesday ➡️Second❓for TONIGHT'S discussion!! @WuGiOnc @SMKangMD @MPishvaian For pts with met BRAF V600E mutant (+) #colorectalcancer, OS for encorafenib + cetuximab > FOLFIRI/cetuximab or irinotecan/cetuximab in the 2nd or 3rd line setting? (Twitter) - Mar 9, 2021
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: RAINFOREST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials. (Pubmed Central) - Mar 9, 2021
We demonstrate the performance of RAINFOREST on the CAIRO2 dataset, a phase III clinical trial which tested the addition of cetuximab treatment for metastatic colorectal cancer and concluded there was no benefit...Guchelaar (h.j.guchelaar@lumc.nl). Supplementary data are available at Bioinformatics online.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells. (Pubmed Central) - Mar 9, 2021
A mathematical model of the Ras activation cycle predicts that the inhibitor severely reduces the proliferation of different Ras-driven cancer cells, effectively cooperating with Cetuximab to reduce proliferation even of Cetuximab-resistant cancer cell lines. Experimental data confirm the model prediction, indicating that the pan-Ras inhibitor is an appropriate candidate for medicinal chemistry efforts tailored at improving its currently unsatisfactory affinity.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Triplet induction chemotherapy followed by less invasive surgery without reconstruction for human papillomavirus-associated oropharyngeal cancers: Why is it successful or unsuccessful? (Pubmed Central) - Mar 9, 2021
Experimental data confirm the model prediction, indicating that the pan-Ras inhibitor is an appropriate candidate for medicinal chemistry efforts tailored at improving its currently unsatisfactory affinity. Upfront ICT using highly responsive triplet chemotherapeutic regimens may enable us to perform less invasive surgery without free-flap reconstruction and to avoid postoperative irradiation to the locoregional field through excellent postoperative pathological features.
- ||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
CUP: CDKN2ab and EGFR amp treated with palbociclib and erlotinib and cetuximab (Twitter) - Mar 8, 2021
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, HEOR: Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. (Pubmed Central) - Mar 6, 2021
These considerations limit generalizability of outcomes to other countries, or within the German healthcare setting. Based on our analyses, FOLFIRI-cet is cost-effective compared with FOLFIRI-bev in patients with RAS wt mCRC, with ICERs well below willingness-to-pay thresholds for diseases with a high burden.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. (Pubmed Central) - Mar 6, 2021
Biomarkers predicting radioresistance should be characterized in p16 positive tumors before widely embarking on de-escalated CRT protocols. Another concern is how to decrease the number of true or marginal misses in p16 negative cases despite multimodality imaging-based target delineation.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda, U3-1565 / Daiichi Sankyo
Clinical, P1 data, Journal: Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer. (Pubmed Central) - Mar 4, 2021
The efficacy of this combination therapy after progression on Cetu/Pani was negligible. Trial Registration: UMIN000013006.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date, Metastases: PACER: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 4, 2021
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Trial Registration: UMIN000013006. Trial completion date: Feb 2018 --> Dec 2022 | Trial primary completion date: Sep 2017 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer (clinicaltrials.gov) - Mar 4, 2021
P2, N=108, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Trial completion date: Feb 2018 --> Dec 2022 | Trial primary completion date: Sep 2017 --> Dec 2021 Trial completion date: Dec 2017 --> Dec 2022 | Trial primary completion date: Mar 2015 --> Dec 2021
- | Vistide (cidofovir) / Gilead, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Differential Efficacy of Novel Antiviral Substances in 3D and Monolayer Cell Culture. (Pubmed Central) - Mar 4, 2021
Antiviral activity of erlotinib and osimertinib was nearly unaffected by the cultivation method similar to the virus-directed antivirals tecovirimat and cidofovir...100-fold more efficient against CPXV in the 3D infection model, similar to previous results with gefitinib...However, in contrast to virus-directed inhibitors, in vitro efficacy of host-directed antivirals might be seriously affected by cell cultivation. Results obtained for afatinib and cetuximab suggest that screening of such drugs in standard monolayer culture might underestimate their potential as antivirals.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells. (Pubmed Central) - Mar 4, 2021
Each conjugate shows high specificity for cells expressing human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), respectively, and potent activity across six Tmab- and Cmab-resistant cell lines. The conjugates also exhibit increased pharmacokinetics and pronounced in vivo safety, which shows promise for further therapeutic development.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
LOL - I do not use EGFR mAbs in R-sided ca in 2nd line, but I would use them after exhaustion of all other options (after Rego + TAS). Brule EJC 2015 showed moderate separation of OS (not PFS) curves in CO.17 - last line single agent cetuximab. Not impressive, though. @OncoAlert (Twitter) - Mar 3, 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab enhances the anti-tumor function of macrophages in an IL-6 dependent manner. (Pubmed Central) - Mar 3, 2021
The conjugates also exhibit increased pharmacokinetics and pronounced in vivo safety, which shows promise for further therapeutic development. These results indicate a new macrophage-based molecular mechanism explaining the effect of cetuximab in treatment of colorectal cancer.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Preferred use of cetuximab-plus-paclitaxel over nivolumab for patients with platinum-refractory head and neck cancer () - Mar 2, 2021 - Abstract #JSMO2021JSMO_1294;
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck squamous cell carcinoma patients ineligible for TPF () - Mar 2, 2021 - Abstract #JSMO2021JSMO_1286;
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: A prospective observation study [JROSG12-2] (Track 13) - Mar 2, 2021 - Abstract #JSMO2021JSMO_540;
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Pneumonitis is Common in Patients with Sequential Nivolumab and Cetuximab Treatment (Track 5) - Mar 2, 2021 - Abstract #JSMO2021JSMO_313;
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Liquid biopsy, Biopsy: LIBImAb: Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (clinicaltrials.gov) - Mar 1, 2021
P3, N=280, Not yet recruiting, Sponsor: Azienda Unit
- | EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial completion date, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Mar 1, 2021
P1, N=30, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
These results indicate a new macrophage-based molecular mechanism explaining the effect of cetuximab in treatment of colorectal cancer. Trial completion date: Jun 2021 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Neoadjuvant therapy of cetuximab combined with chemoradiotherapy in rectal cancer: A single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. (Pubmed Central) - Feb 27, 2021
The raise of R0-resection rate needed to be verified by more high-quality and well-designed RCTs. Meanwhile, the morbidity of toxicity was relatively mild and acceptable.
- || Cyramza (ramucirumab) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report. (Pubmed Central) - Feb 27, 2021
The paclitaxel chemotherapy with ramucirumab is effective and safe in HD patients with metastatic gastric cancer. As seen in patients with normal kidney function, ramucirumab can be safely administered without a dose reduction.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer. (Pubmed Central) - Feb 27, 2021
As seen in patients with normal kidney function, ramucirumab can be safely administered without a dose reduction. SATB-2, ORP-1, MYB, and CDX-2 were related to cetuximab sensitivity as well as enhanced tumor immune cell infiltration in patients with CRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Injectable Thermo-Sensitive Chitosan Hydrogel Containing CPT-11-Loaded EGFR-Targeted Graphene Oxide and SLP2 shRNA for Localized Drug/Gene Delivery in Glioblastoma Therapy. (Pubmed Central) - Feb 26, 2021
Overall, we have demonstrated the novelty of this thermosensitive hydrogel to be an excellent depot for the co-delivery of anticancer drugs and siRNA. The in situ forming hydrogel will not only provide extended drug release but also combine the advantages offered by the chitosan-based copolymer structure for siRNA delivery to broaden treatment modalities in cancer therapy.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Erbitux implies the existence of erbigown 👑 (Twitter) - Feb 25, 2021
- | Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy (clinicaltrials.gov) - Feb 25, 2021
P2, N=135, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
The in situ forming hydrogel will not only provide extended drug release but also combine the advantages offered by the chitosan-based copolymer structure for siRNA delivery to broaden treatment modalities in cancer therapy. Trial primary completion date: Nov 2020 --> Feb 2021